Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor.

J Cell Physiol

Division of Oral and Maxillofacial Reconstructive Surgery, Department of Oral and Maxillofacial Surgery, Kyushu Dental College, Kitakyushu, Japan.

Published: September 2008

Heparin demonstrates several kinds of biological activities by binding to various extracellular molecules and plays pivotal roles in bone metabolism. However, the role of heparin in the biological activity of bone morphogenetic protein (BMP) remains unclear. In the present study, we examined whether heparin has the effects on osteoblast differentiation induced by BMP-2 in vitro and also elucidated the precise mechanism by which heparin regulates bone metabolism induced by this molecule. Our results showed that heparin inhibited alkaline phosphatase (ALP) activity and mineralization in osteoblastic cells cultured with BMP-2. Heparin was found to suppress the mRNA expressions of osterix, Runx2, ALP and osteocalcin, as well as phosphorylation of Smad1/5/8 and p38 MAPK. Further, heparin bound to both BMP-2 and BMP receptor (BMPR). These results suggest that heparin suppresses BMP-2-BMPR binding, and inhibits BMP-2 osteogenic activity in vitro.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.21468DOI Listing

Publication Analysis

Top Keywords

heparin
9
inhibits bmp-2
8
bmp-2 osteogenic
8
bmp-2 bmp
8
bmp receptor
8
bone metabolism
8
bmp-2
6
heparin inhibits
4
osteogenic bioactivity
4
bioactivity binding
4

Similar Publications

Safety profiles of fondaparinux in pregnant women: a systematic review and meta-analysis.

Eur J Clin Pharmacol

January 2025

Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, No. 20, Renmin South Road, Section 3, Chengdu, 610041, Sichuan Province, China.

Background: The prevalence of conditions necessitating anticoagulation therapy among pregnant women has been steadily increasing. Although low-molecular-weight heparin (LMWH) is commonly used, several studies have investigated the use of fondaparinux in pregnant women. However, the safety profile of fondaparinux in this population remains to be fully elucidated.

View Article and Find Full Text PDF

Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: network meta-analysis.

Front Pharmacol

January 2025

Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.

Objectives: Evidences for anticoagulation strategies in cirrhotic with portal vein thrombosis (PVT) are still insufficient. This study aims to comprehensively compare the therapeutic effects of different therapeutic therapeutic measures in individuals suffering from cirrhosis with PVT, with the ultimate goal of providing evidence-based recommendations for thrombolytic therapy in this population.

Methods: Starting from 20 October 2023, a comprehensive search about therapeutic strategies for portal vein thrombosis in cirrhosis was conducted on PubMed, EMBASE, and Cochrane Library.

View Article and Find Full Text PDF

Proteomic Identification and Functional Analysis of Reveals Heparin-Binding Proteins.

J Trop Med

January 2025

National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Laboratory of Parasite and Vector Biology, Ministry of Public Health, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai 200025, China.

Glycosaminoglycan (GAG) molecules on the surface of red blood cells play an important regulatory role in the invasion of merozoites of apicomplexan protozoa. Heparan sulfate, a type of GAG molecule, has been identified as an important receptor facilitating the invasion of red blood cells by these parasites. Proteins in the parasite that exhibit strong affinity for heparin may play a pivotal role in this invasion process.

View Article and Find Full Text PDF

Objective: To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery.

Methods: Sixty patients diagnosed with lower extremity deep vein thrombosis (DVT) following thoracoscopic lung cancer surgery were randomly assigned to two groups: the experimental group comprising 30 patients treated with rivaroxaban, and the control group consisting of 30 patients treated with low molecular weight heparin (LMWH). The fundamental clinical characteristics of patients in both groups were documented, encompassing parameters, along with pre- and post-surgical lower limb vascular ultrasound findings.

View Article and Find Full Text PDF

The present study employed a large scaled multicenter nationwide study data analysis to elucidate the impact of thromboembolism prophylaxis (TEP) in the context of bariatric and metabolic surgery and to investigate the peri- and postoperative complications associated with TEP. A total of 63,909 patients who underwent primary bariatric surgery between 2005 and 2020 were included in the analysis. The data were collected prospectively and multicentrically in the German Bariatric Surgery Registry (GBSR) and subsequently analyzed retrospectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!